Citizens Financial Group Inc. RI bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $160,000. Citizens Financial Group Inc. RI owned approximately 0.07% of Perspective Therapeutics as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics in the fourth quarter worth $33,000. Aigen Investment Management LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $34,000. Vontobel Holding Ltd. bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $51,000. Trueblood Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 37.0% in the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock valued at $71,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Koa Wealth Management LLC bought a new position in shares of Perspective Therapeutics during the fourth quarter worth about $83,000. 54.66% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on CATX. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $14.56.
Perspective Therapeutics Stock Performance
Shares of NYSE:CATX opened at $2.59 on Friday. The firm’s 50 day moving average is $3.14 and its two-hundred day moving average is $7.32. Perspective Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $19.05.
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Read More
- Five stocks we like better than Perspective Therapeutics
- Business Services Stocks Investing
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to trade penny stocks: A step-by-step guide
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to Invest in the FAANG Stocks
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding CATX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perspective Therapeutics, Inc. (NYSE:CATX – Free Report).
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.